LecaneMab is a monoclonal antibody therapy designed to target and reduce amyloid plaques in the brain. It is administered via intravenous infusion to slow cognitive decline in early-stage Alzheimer’s disease. Patients with mild symptoms and confirmed amyloid pathology benefit most, as it helps preserve memory and daily function when started early.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends